Legend Biotech Corporation
LEGNNASDAQHealthcare● Active
$31.37
$-1.25(-3.83%)
Market Cap$5.8B
P/E Ratio—
52W High$45.297
52W Low$16.24
Legend Biotech Corporation (LEGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LEGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.15
Est. -$0.02 · -650.0%
Revenue
$0.31B
Est. $0.31B · -0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
LEGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | $0.12 | — | — | — | $0.36B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.02 | -$0.15 | -650.0% | $0.31B | $0.31B | -0.5% |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$0.17 | -$0.08 | +52.9% | $0.31B | $0.31B | -0.5% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.13 | -$0.11 | +15.4% | $0.27B | $0.31B | -12.0% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.22 | -$0.34 | -54.5% | $0.26B | $0.28B | -8.0% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.40 | -$0.07 | +82.5% | $0.20B | $0.22B | -10.5% |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.39 | -$0.15 | +61.5% | $0.19B | $0.19B | -2.5% |
| ▲ Q3 FY2024 | Aug 9, 2024 | -$0.54 | -$0.05 | +90.7% | $0.19B | $0.13B | +38.5% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
$0.12
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.15
EPS Est.
-$0.02
EPS Surpr.
-650.0%
Revenue
$0.31B
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.17
EPS Surpr.
+52.9%
Revenue
$0.31B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.13
EPS Surpr.
+15.4%
Revenue
$0.27B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.22
EPS Surpr.
-54.5%
Revenue
$0.26B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.40
EPS Surpr.
+82.5%
Revenue
$0.20B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.39
EPS Surpr.
+61.5%
Revenue
$0.19B
Q3 FY2024
Aug 9, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.54
EPS Surpr.
+90.7%
Revenue
$0.19B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.83 | $0.91 | $1.04 | 3 |
| Q3 FY2028 | $0.30 | $0.33 | $0.37 | 2 |
| Q2 FY2028 | $0.27 | $0.30 | $0.34 | 2 |
| Q1 FY2028 | $0.22 | $0.24 | $0.28 | 3 |
| Q4 FY2027 | $0.31 | $0.34 | $0.39 | 2 |
| Q3 FY2027 | $0.29 | $0.32 | $0.36 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.5B | $0.5B | $0.6B | 4 |
| Q3 FY2028 | $0.5B | $0.5B | $0.6B | 4 |
| Q2 FY2028 | $0.4B | $0.5B | $0.5B | 5 |
| Q1 FY2028 | $0.4B | $0.4B | $0.5B | 2 |
| Q4 FY2027 | $0.5B | $0.5B | $0.6B | 3 |
| Q3 FY2027 | $0.4B | $0.5B | $0.5B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -650.0% | $25.58 | $28.26 | +10.48% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +52.9% | $19.14 | $19.56 | +2.19% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +15.4% | $32.03 | $31.18 | -2.65% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -54.5% | $37.00 | $36.24 | -2.05% |
| ▲ Q2 FY2025 | May 13, 2025 | +82.5% | $32.38 | $31.08 | -4.01% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +61.5% | $34.03 | $37.19 | +9.29% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +90.7% | $56.91 | $55.90 | -1.77% |
| ▲ Q2 FY2024 | May 13, 2024 | +44.8% | $43.24 | $42.97 | -0.62% |
Q2 FY2026+10.48%
Report Date
May 12, 2026
EPS Beat/Miss
-650.0%
Price Before
$25.58
Price After
$28.26
Q1 FY2026+2.19%
Report Date
Mar 10, 2026
EPS Beat/Miss
+52.9%
Price Before
$19.14
Price After
$19.56
Q4 FY2025-2.65%
Report Date
Nov 12, 2025
EPS Beat/Miss
+15.4%
Price Before
$32.03
Price After
$31.18
Q3 FY2025-2.05%
Report Date
Aug 11, 2025
EPS Beat/Miss
-54.5%
Price Before
$37.00
Price After
$36.24
Q2 FY2025-4.01%
Report Date
May 13, 2025
EPS Beat/Miss
+82.5%
Price Before
$32.38
Price After
$31.08
Q1 FY2025+9.29%
Report Date
Mar 11, 2025
EPS Beat/Miss
+61.5%
Price Before
$34.03
Price After
$37.19
Q3 FY2024-1.77%
Report Date
Aug 9, 2024
EPS Beat/Miss
+90.7%
Price Before
$56.91
Price After
$55.90
Q2 FY2024-0.62%
Report Date
May 13, 2024
EPS Beat/Miss
+44.8%
Price Before
$43.24
Price After
$42.97
Avg Beat Reaction+0.40%
Avg Miss Reaction+4.21%
Beat Rate6 / 8 quarters
Largest Move+10.48% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LEGN ends December
Legend Biotech Corporation (LEGN) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.15 — missing the analyst consensus of $-0.02 by -650.0%. The next LEGN earnings date is expected around September 1, 2026.
Each quarter, investors track LEGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LEGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LEGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LEGN earnings · 5 questionsLegend Biotech Corporation's next earnings report is expected around September 1, 2026. LEGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LEGN historically reports after market close (AMC).
LEGN earnings datewhen is LEGN earningsLEGN next earnings datewhen does LEGN report earningsLEGN earnings calendar
▸ Source: FMP · Legend Biotech Corporation SEC filings · US GAAP · Legend Biotech Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026